Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer? | Zendy

Howard B. Lieberman | Zendy

Open Access

Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

Author(s) -

Howard B. Lieberman

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2019.12.102

Subject(s) - olaparib , ovarian cancer , medicine , oncology , cancer , maintenance therapy , biology , chemotherapy , poly adp ribose polymerase , genetics , polymerase , gene

Ovarian cancer is highly prevalent and the second most deadly gynecological cancer (1). It is estimated that globally in the year 2018 there were 295,414 new cases and 184,799 deaths because of this disease. Epithelial ovarian carcinomas account for 85% to 90% of all malignant ovarian cancers, and more than half of those are the histotype serous carcinoma (2).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research